Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LANCL2 | Q9NS86 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
| ▸ | UGT2B7 | P16662 | 2/20 | 0.32 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.32 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.32 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9287929 | 1.00 | LANCL2 (0.32) | LANCL2HCRTR1HCRTR2UGT2B7TMEM97 | |
| SCHEMBL3001100 | 1.00 | LANCL2 (0.32) | LANCL2HCRTR1HCRTR2UGT2B7TMEM97 | |
| SCHEMBL17822576 | 1.00 | LANCL2 (0.32) | LANCL2HCRTR1HCRTR2UGT2B7TMEM97 | |
| SCHEMBL3336877 | 1.00 | LANCL2 (0.32) | LANCL2HCRTR1HCRTR2UGT2B7TMEM97 | |
| SCHEMBL3001106 | 1.00 | LANCL2 (0.32) | LANCL2HCRTR1HCRTR2UGT2B7TMEM97 | |
| SCHEMBL3336886 | 1.00 | LANCL2 (0.32) | LANCL2HCRTR1HCRTR2UGT2B7TMEM97 | |
| SCHEMBL3001104 | 1.00 | LANCL2 (0.32) | LANCL2HCRTR1HCRTR2UGT2B7TMEM97 | |
| SCHEMBL15345921 | 0.82 | UGT2B7 (0.33) | LANCL2UGT2B7 | |
| SCHEMBL15345922 | 0.82 | UGT2B7 (0.33) | LANCL2UGT2B7 | |
| SCHEMBL3989029 | 0.81 | HCAR2 (0.39) | HCRTR1HCRTR2CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10633390-B2 | Process for the preparation of [(1S,2R)-3-[[(4-aminophenyl)sulfonyl] (2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-carbamic acid (3R,3AS,6AR)hexahydro furo [2,3-B]furan-3-YL ester and its amorphous form | MSN LABORATORIES PRIVATE LIMITED (IN) | 2020-04-28 | — | — | US | claimed |
| US-20180370982-A1 | PROCESS FOR THE PREPARATION OF [(1S,2R)-3-[[(4-AMINOPHENYL)SULFONYL] (2-METHYLPROPYL)AMINO]-2-HYDROXY-1-(PHENYLMETHYL)PROPYL]-CARBAMIC ACID (3R,3AS,6AR)HEXAHYDRO FURO[2,3-B]FURAN-3-YL ESTER AND ITS AMORPHOUS FORM | MSN LABORATORIES PRIVATE LIMITED (IN) | 2018-12-27 | — | — | US | claimed |
| EP-3313847-A1 | PROCESS FOR THE PREPARATION OF [(1 S,2R)-3-[[(4-AMINOPHENYL)SULFONYL](2-METHYLPROPYL)AMINO]-2-HYDROXY-1 -(PHENYLMETHYL)PROPYL]-CARBAMIC ACID (3R,3AS,6AR)HEXAHYDRO FURO[2,3-B]FURAN-3-YL ESTER AND ITS AMORPHOUS FORM | MSN Laboratories Private Limited (IN) | 2018-05-02 | — | — | EP | claimed |
| WO-2016207907-A1 | PROCESS FOR THE PREPARATION OF [(1 S,2R)-3-[[(4-AMINOPHENYL)SULFONYL] (2-METHYLPROPYL)AMINO]-2-HYDROXY-1 -(PHENYLMETHYL)PROPYL]-CARBAMIC ACID (3R,3AS,6AR)HEXAHYDRO FURO[2,3-B]FURAN-3-YL ESTER AND ITS AMORPHOUS FORM | MSN LABORATORIES PRIVATE LIMITED (IN) | 2016-12-29 | — | — | WO | claimed |
| CN-113816978-A | Diamine-boronic ester complex and preparation method and application thereof | 北京大学 | 2021-12-21 | — | — | CN | disclosed |
| CN-107980042-B | Aryldihydro-2H-benzo [ b ] [1,4] oxazine sulfonamides and related compounds as ROR gamma agonists and for the treatment of disease | 莱斯拉公司 | 2021-10-08 | — | — | CN | disclosed |
| US-11059796-B2 | Aryl dihydro-2H benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-07-13 | — | — | US | disclosed |
| US-20210061778-A1 | ARYL DIHYDRO-2H BENZO[B][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORY AND THE TREATMENT OF DISEASE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2021-03-04 | — | — | US | disclosed |
| EP-3344630-B1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRROLO[1,2-C]IMIDAZOL-3-ONE ANTIBACTERIAL COMPOUNDS | IDORSIA PHARMACEUTICALS LTD (CH) | 2020-12-09 | — | — | EP | disclosed |
| US-10633390-B2 | Process for the preparation of [(1S,2R)-3-[[(4-aminophenyl)sulfonyl] (2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-carbamic acid (3R,3AS,6AR)hexahydro furo [2,3-B]furan-3-YL ester and its amorphous form | MSN LABORATORIES PRIVATE LIMITED (IN) | 2020-04-28 | — | — | US | disclosed |
| US-10314823-B2 | Substituted 1,2-dihydro-3H-pyrrolo[1,2-c]imidazol-3-one antibacterial compounds | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-06-11 | — | — | US | disclosed |
| US-20190077797-A1 | PROCESSES FOR PREPARING 2-DIHALO RIBOLACTONES | EMORY UNIVERSITY | 2019-03-14 | — | — | US | disclosed |
| WO-2017037221-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRROLO[1,2-C]IMIDAZOL-3-ONE ANTIBACTERIAL COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2017-03-09 | — | — | WO | disclosed |
| WO-2016207907-A1 | PROCESS FOR THE PREPARATION OF [(1 S,2R)-3-[[(4-AMINOPHENYL)SULFONYL] (2-METHYLPROPYL)AMINO]-2-HYDROXY-1 -(PHENYLMETHYL)PROPYL]-CARBAMIC ACID (3R,3AS,6AR)HEXAHYDRO FURO[2,3-B]FURAN-3-YL ESTER AND ITS AMORPHOUS FORM | MSN LABORATORIES PRIVATE LIMITED (IN) | 2016-12-29 | — | — | WO | disclosed |
| CN-101848905-A | Process for the enantioselective preparation of pregabalin | ESTEVE LABOR DR | 2010-09-29 | — | — | CN | disclosed |
| US-20100197939-A1 | PROCESS FOR THE ENANTIOSELECTIVE PREPARATION OF PREGABALIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-08-05 | — | — | US | disclosed |
| US-6518305-B1 | For inhibiting neuraminidases from disease- causing microorganisms, especially, influenza neuraminidase | ABBOTT LABORATORIES | 2003-02-11 | — | — | US | disclosed |
| WO-2001028979-A2 | INHIBITORS OF NEURAMINIDASES | ABBOTT LABORATORIES (US) | 2001-04-26 | — | — | WO | disclosed |
| EP-1087938-A1 | INHIBITORS OF NEURAMINIDASES | ABBOTT LABORATORIES (US) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999054290-A1 | INHIBITORS OF NEURAMINIDASES | ABBOTT LABORATORIES (US) | 1999-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077797-A1 | PROCESSES FOR PREPARING 2-DIHALO RIBOLACTONES | DERA, DPYD, DUS2 | LANCL2 2389/4885HCRTR1 2336/4885HCRTR2 2353/4885 |
| US-11059796-B2 | Aryl dihydro-2H benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | RORB, RORA, RORC | LANCL2 3685/4885HCRTR1 341/4885HCRTR2 275/4885 |
| US-10314823-B2 | Substituted 1,2-dihydro-3H-pyrrolo[1,2-c]imidazol-3-one antibacterial compounds | MRPL21, MRM1, MT-CO1 | LANCL2 3554/4885HCRTR1 3544/4885HCRTR2 4587/4885 |
| US-10633390-B2 | Process for the preparation of [(1S,2R)-3-[[(4-aminophenyl)sulfonyl] (2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-carbamic acid (3R,3AS,6AR)hexahydro furo [2,3-B]furan-3-YL ester and its amorphous form | FFAR1, CYP2S1, CYP1B1 | LANCL2 2404/4885HCRTR1 1258/4885HCRTR2 2134/4885 |
| US-20100197939-A1 | PROCESS FOR THE ENANTIOSELECTIVE PREPARATION OF PREGABALIN | GABRE, CYP2D6, GABRG2 | LANCL2 1467/4885HCRTR1 1977/4885HCRTR2 1411/4885 |
| US-20180370982-A1 | PROCESS FOR THE PREPARATION OF [(1S,2R)-3-[[(4-AMINOPHENYL)SULFONYL] (2-METHYLPROPYL)AMINO]-2-HYDROXY-1-(PHENYLMETHYL)PROPYL]-CARBAMIC ACID (3R,3AS,6AR)HEXAHYDRO FURO[2,3-B]FURAN-3-YL ESTER AND ITS AMORPHOUS FORM | FFAR1, CYP2S1, FFAR3 | LANCL2 2343/4885HCRTR1 1277/4885HCRTR2 2123/4885 |
| US-20210061778-A1 | ARYL DIHYDRO-2H BENZO[B][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORY AND THE TREATMENT OF DISEASE | RORB, RORA, RORC | LANCL2 3625/4885HCRTR1 273/4885HCRTR2 230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.